Pub Date : 2025-01-20DOI: 10.2174/0113892010363803250110052220
Nadeem Kizilbash, Nida Suhail, Mohamed Soliman, Ranya Mohammed Elmagzoub, Madison Marsh, Rimsha Farooq
Since their inception, therapeutic or prophylactic vaccines have emerged as promising candidates for the prevention or treatment of infections and various diseases, including cancer and autoimmune disorders. In recent times, gold nanoparticles (GNPs) have acquired active roles in the field of vaccine development due to their intrinsic capacity to adjust and enhance the immune response. Due to their characteristics, GNPs can exert optimal effects as both delivery vehicles and adjuvants. Despite their significant importance in vaccinology, numerous obstacles need to be overcome before GNPs can be used in the formulations of vaccines in clinical settings. The current review summarizes the latest and successful use of gold nanoparticles as a viable method for developing a new generation of vaccines.
{"title":"Nanoparticles as Delivery Vehicles for Vaccines: The Use of Gold Nanoparticles.","authors":"Nadeem Kizilbash, Nida Suhail, Mohamed Soliman, Ranya Mohammed Elmagzoub, Madison Marsh, Rimsha Farooq","doi":"10.2174/0113892010363803250110052220","DOIUrl":"https://doi.org/10.2174/0113892010363803250110052220","url":null,"abstract":"<p><p>Since their inception, therapeutic or prophylactic vaccines have emerged as promising candidates for the prevention or treatment of infections and various diseases, including cancer and autoimmune disorders. In recent times, gold nanoparticles (GNPs) have acquired active roles in the field of vaccine development due to their intrinsic capacity to adjust and enhance the immune response. Due to their characteristics, GNPs can exert optimal effects as both delivery vehicles and adjuvants. Despite their significant importance in vaccinology, numerous obstacles need to be overcome before GNPs can be used in the formulations of vaccines in clinical settings. The current review summarizes the latest and successful use of gold nanoparticles as a viable method for developing a new generation of vaccines.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-20DOI: 10.2174/0113892010344931241220042746
Bhaveshkumar A Patel, Ankur Vashi, Ramakrishna Borra, Mehul Patel
Cancer treatment has evolved significantly over the years, incorporating a range of modalities including surgery, radiation, chemotherapy, and immunotherapy. However, challenges such as drug resistance, systemic toxicity, and poor targeting necessitate innovative approaches. Peptides have gained attention in cancer therapy due to their specificity, potency, and ability to modulate various biological pathways. Peptide-based drugs can act as hormones, enzyme inhibitors, or targeting ligands, contributing to their versatile role in cancer treatment. However, peptides face several challenges, including instability, rapid degradation, and poor bioavailability. One promising strategy is the use of niosomal delivery systems for peptidebased therapies. Niosomes, which resemble liposomes in structure, are vesicles based on nonionic surfactants. They are composed of a bilayer created through the self-assembly of non-ionic surfactants in water, enabling them to encapsulate hydrophilic, lipophilic, and amphiphilic drugs. Their unique properties, such as biocompatibility, biodegradability, and ability to encapsulate diverse therapeutic agents, make them suitable for drug delivery applications. This review aims to explore how the niosomal preparation of peptides can revolutionize oncology drugs by overcoming critical challenges like drug resistance, systemic toxicity, poor targeting, instability, rapid degradation, and low bioavailability. This review aims to explore how niosomes can specifically address key limitations in cancer therapy, including targeting, bioavailability, and stability of peptide-based drugs. By consolidating recent advancements, the review sheds light on how niosomal encapsulation can overcome barriers in cancer treatment and improve therapeutic outcomes for patients.
多年来,癌症治疗发生了重大变化,包括手术、放疗、化疗和免疫治疗等一系列方式。然而,诸如耐药、全身毒性和靶向性差等挑战需要创新的方法。多肽由于其特异性、效力和调节多种生物途径的能力而在癌症治疗中受到关注。基于肽的药物可以作为激素、酶抑制剂或靶向配体,有助于它们在癌症治疗中的多功能作用。然而,多肽面临着一些挑战,包括不稳定性、快速降解和生物利用度差。一个有希望的策略是使用niosomal递送系统进行基于肽的治疗。乳质体是一种以非离子表面活性剂为基础的囊泡,其结构与脂质体相似。它们由非离子表面活性剂在水中自组装形成的双分子层组成,使它们能够包裹亲水、亲脂和两亲性药物。它们独特的特性,如生物相容性、生物可降解性和包封多种治疗剂的能力,使它们适合于药物输送应用。本综述旨在探讨肽的niosomal preparation of peptides如何通过克服诸如耐药、全身毒性、靶向性差、不稳定性、快速降解和低生物利用度等关键挑战来彻底改变肿瘤药物。这篇综述的目的是探讨肿瘤小体如何专门解决癌症治疗的关键限制,包括靶向性、生物利用度和肽类药物的稳定性。通过巩固最近的进展,本综述揭示了niosomal encapsulation如何克服癌症治疗中的障碍并改善患者的治疗结果。
{"title":"Niosomal Encapsulation of Anti-Cancer Peptides: A Revolutionary Strategy in Cancer Therapy.","authors":"Bhaveshkumar A Patel, Ankur Vashi, Ramakrishna Borra, Mehul Patel","doi":"10.2174/0113892010344931241220042746","DOIUrl":"https://doi.org/10.2174/0113892010344931241220042746","url":null,"abstract":"<p><p>Cancer treatment has evolved significantly over the years, incorporating a range of modalities including surgery, radiation, chemotherapy, and immunotherapy. However, challenges such as drug resistance, systemic toxicity, and poor targeting necessitate innovative approaches. Peptides have gained attention in cancer therapy due to their specificity, potency, and ability to modulate various biological pathways. Peptide-based drugs can act as hormones, enzyme inhibitors, or targeting ligands, contributing to their versatile role in cancer treatment. However, peptides face several challenges, including instability, rapid degradation, and poor bioavailability. One promising strategy is the use of niosomal delivery systems for peptidebased therapies. Niosomes, which resemble liposomes in structure, are vesicles based on nonionic surfactants. They are composed of a bilayer created through the self-assembly of non-ionic surfactants in water, enabling them to encapsulate hydrophilic, lipophilic, and amphiphilic drugs. Their unique properties, such as biocompatibility, biodegradability, and ability to encapsulate diverse therapeutic agents, make them suitable for drug delivery applications. This review aims to explore how the niosomal preparation of peptides can revolutionize oncology drugs by overcoming critical challenges like drug resistance, systemic toxicity, poor targeting, instability, rapid degradation, and low bioavailability. This review aims to explore how niosomes can specifically address key limitations in cancer therapy, including targeting, bioavailability, and stability of peptide-based drugs. By consolidating recent advancements, the review sheds light on how niosomal encapsulation can overcome barriers in cancer treatment and improve therapeutic outcomes for patients.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-17DOI: 10.2174/0113892010343782250110113310
Ian Jhemes Oliveira Sousa, Kerolayne De Melo Nogueira, Rita de Cássia Meneses Oliveira
The traditional use of plants of the Cinnamomum genus dates back to traditional Eastern medicine for millennia and they have also been used in Western integrative medicine practices, especially for their anti-inflammatory activity. In the context of chemical diversity, the absolute majority of species in this genus have cinnamaldehyde as the majority component, which in turn holds the title of the active ingredient, whose biological effect profile has already been demonstrated in numerous experiments in acute and chronic inflammatory conditions. In this context, the objective of this research was to investigate how cinnamaldehyde can influence inflammatory phenomena. To this end, the data search was carried out in Pub- Med, SciELO, and LILACS databases using the following descriptors: "cinnamaldehyde OR cinnamaldehyde" and "inflammation". Next, the methodological quality of the selected articles was checked, excluding repeated studies, which were purely in silico and not relevant to the construction of this research. The findings showed cinnamaldehyde to modulate the inflammatory response by inhibiting pro-inflammatory mediators and important signaling trajectories, including NF-κB, NLRP3 inflammasome, TGF-β/Smads, and the NRF2/ARE antioxidant pathway. Cinnamaldehyde's scope of investigation also involves aspects of translational science, exhibiting therapeutic effects in human models, which suggests that it may have clinical relevance. The data support that cinnamaldehyde is a promising candidate for development as a treatment in inflammatory pathologies.
肉桂属植物的传统用途可以追溯到几千年前的传统东方医学,它们也被用于西方综合医学实践,特别是它们的抗炎活性。在化学多样性的背景下,肉桂属的绝大多数物种都以肉桂醛为主要成分,这反过来又拥有活性成分的头衔,其生物效应已经在许多急性和慢性炎症条件下的实验中得到证实。在这种情况下,本研究的目的是研究肉桂醛如何影响炎症现象。为此,在Pub- Med、SciELO和LILACS数据库中进行数据检索,检索词为“cinnamaldehyde OR cinnamaldehyde”和“inflammation”。接下来,检查所选文章的方法学质量,排除重复研究,这些研究纯粹是在计算机上进行的,与本研究的构建无关。研究结果表明,肉桂醛通过抑制促炎介质和重要的信号通路,包括NF-κB、NLRP3炎性体、TGF-β/Smads和NRF2/ARE抗氧化途径,调节炎症反应。肉桂醛的研究范围还涉及转化科学的各个方面,在人体模型中显示出治疗效果,这表明它可能具有临床相关性。数据支持肉桂醛是一个有希望的候选发展作为治疗炎症病理。
{"title":"Biotechnological Perspectives on the Therapeutic Potential of Phenylpropanoid Cinnamaldehyde in Inflammatory Diseases: Signaling Pathways.","authors":"Ian Jhemes Oliveira Sousa, Kerolayne De Melo Nogueira, Rita de Cássia Meneses Oliveira","doi":"10.2174/0113892010343782250110113310","DOIUrl":"https://doi.org/10.2174/0113892010343782250110113310","url":null,"abstract":"<p><p>The traditional use of plants of the Cinnamomum genus dates back to traditional Eastern medicine for millennia and they have also been used in Western integrative medicine practices, especially for their anti-inflammatory activity. In the context of chemical diversity, the absolute majority of species in this genus have cinnamaldehyde as the majority component, which in turn holds the title of the active ingredient, whose biological effect profile has already been demonstrated in numerous experiments in acute and chronic inflammatory conditions. In this context, the objective of this research was to investigate how cinnamaldehyde can influence inflammatory phenomena. To this end, the data search was carried out in Pub- Med, SciELO, and LILACS databases using the following descriptors: \"cinnamaldehyde OR cinnamaldehyde\" and \"inflammation\". Next, the methodological quality of the selected articles was checked, excluding repeated studies, which were purely in silico and not relevant to the construction of this research. The findings showed cinnamaldehyde to modulate the inflammatory response by inhibiting pro-inflammatory mediators and important signaling trajectories, including NF-κB, NLRP3 inflammasome, TGF-β/Smads, and the NRF2/ARE antioxidant pathway. Cinnamaldehyde's scope of investigation also involves aspects of translational science, exhibiting therapeutic effects in human models, which suggests that it may have clinical relevance. The data support that cinnamaldehyde is a promising candidate for development as a treatment in inflammatory pathologies.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nature has been acknowledged as a fundamental source of diverse bioactive molecules. Among natural carotenoids, lutein, zeaxanthin, and their oxidative metabolites are specifically deposited in the macular region of living organisms. Lutein and zeaxanthin are carotenoids primarily found in green leafy vegetables, eggs, and various fruits. Lutein and zeaxanthin emerge as the primary carotenoids in the retina, playing a crucial role as photo-protectants to prevent retinal degeneration. The extraction of lutein and zeaxanthin from natural sources involves several techniques, including solvent extraction and supercritical fluid extraction, with an emphasis on optimizing efficiency and yield. Incorporating these carotenoids into functional foods-such as fortified dairy products, baked goods, and snacks-enhances their nutritional profiles and provides significant health benefits. This review examines the sources, stability, bioactivity, and various extraction methods for lutein and zeaxanthin, highlighting their potential for photoprotection, antioxidant activity, and antidiabetic effects. These attributes, combined with innovative extraction techniques, position lutein and zeaxanthin as promising ingredients for functional food applications.
{"title":"Lutein and Zeaxanthin: Source, Extraction, Stability, Bioactivity, and Functional Food Applications.","authors":"Surabhi Pandey, Akansha Gupta, Dipendra Kumar Mahato, Veena Paul, Abhishek Dutt Tripathi, Prasad Rasane, Pradeep Kumar, Madhu Kamle, Shafiul Haque","doi":"10.2174/0113892010334209241206113640","DOIUrl":"10.2174/0113892010334209241206113640","url":null,"abstract":"<p><p>Nature has been acknowledged as a fundamental source of diverse bioactive molecules. Among natural carotenoids, lutein, zeaxanthin, and their oxidative metabolites are specifically deposited in the macular region of living organisms. Lutein and zeaxanthin are carotenoids primarily found in green leafy vegetables, eggs, and various fruits. Lutein and zeaxanthin emerge as the primary carotenoids in the retina, playing a crucial role as photo-protectants to prevent retinal degeneration. The extraction of lutein and zeaxanthin from natural sources involves several techniques, including solvent extraction and supercritical fluid extraction, with an emphasis on optimizing efficiency and yield. Incorporating these carotenoids into functional foods-such as fortified dairy products, baked goods, and snacks-enhances their nutritional profiles and provides significant health benefits. This review examines the sources, stability, bioactivity, and various extraction methods for lutein and zeaxanthin, highlighting their potential for photoprotection, antioxidant activity, and antidiabetic effects. These attributes, combined with innovative extraction techniques, position lutein and zeaxanthin as promising ingredients for functional food applications.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-16DOI: 10.2174/0113892010349200241204062202
Alba Grifoni, John Sidney, Daniela Weiskopf, Richard H Scheuermann, Alessandro Sette
The SARS-CoV-2 pandemic has highlighted the need for society, as a whole, to be prepared against potential pandemics caused by a variety of different viral families of concern. Here, we describe a roadmap towards the identification and validation of conserved T cell epitope regions from Viral Families of Pandemic Potential (VFPP). For each viral family, we select a prototype virus, the sequence of which could be utilized in epitope identification screens. Examples of viral families considered and their respective prototypes (species/ subspecies) are Coronaviridae (Severe Acute Respiratory Syndrome-related Coronavirus/ SARS-CoV-2), Flaviviridae (Dengue virus/DENV2), Togaviridae (Chikungunya virus/ CHIKV), Paramyixoviridae (Morbillivirus/measles), Arenaviridae (Mammarenavirus/ Lassa), and Picornaviridae (Enterovirus C/poliovirus). The peptide sequences encoded in each prototype virus are then analyzed to determine their conservation across different viral taxonomic groups and viral variants derived from each of the VFPP. We outline available methodologies for epitope discovery based on panels of overlapping peptides and bioinformatics- based predictions of HLA-peptide binding, along with high-throughput in vitro assays, with emphasis on addressing coverage of the general worldwide population. Validation can be achieved by a variety of methodologies, including determining HLA restriction and recognition in samples from volunteers convalescent from previous infections or immunized with approved or experimental vaccines, and immunophenotyping of responding T cells. The capacity of these regions to induce crossreactive T cell responses can be tested experimentally with homologous peptides derived from the various viral species of interest. Importantly, they could be considered as a component of pan-viral family vaccines. Conversely, immunogenic regions that are highly specific to a given virus could be of interest for diagnostic applications.
{"title":"A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.","authors":"Alba Grifoni, John Sidney, Daniela Weiskopf, Richard H Scheuermann, Alessandro Sette","doi":"10.2174/0113892010349200241204062202","DOIUrl":"https://doi.org/10.2174/0113892010349200241204062202","url":null,"abstract":"<p><p>The SARS-CoV-2 pandemic has highlighted the need for society, as a whole, to be prepared against potential pandemics caused by a variety of different viral families of concern. Here, we describe a roadmap towards the identification and validation of conserved T cell epitope regions from Viral Families of Pandemic Potential (VFPP). For each viral family, we select a prototype virus, the sequence of which could be utilized in epitope identification screens. Examples of viral families considered and their respective prototypes (species/ subspecies) are Coronaviridae (Severe Acute Respiratory Syndrome-related Coronavirus/ SARS-CoV-2), Flaviviridae (Dengue virus/DENV2), Togaviridae (Chikungunya virus/ CHIKV), Paramyixoviridae (Morbillivirus/measles), Arenaviridae (Mammarenavirus/ Lassa), and Picornaviridae (Enterovirus C/poliovirus). The peptide sequences encoded in each prototype virus are then analyzed to determine their conservation across different viral taxonomic groups and viral variants derived from each of the VFPP. We outline available methodologies for epitope discovery based on panels of overlapping peptides and bioinformatics- based predictions of HLA-peptide binding, along with high-throughput in vitro assays, with emphasis on addressing coverage of the general worldwide population. Validation can be achieved by a variety of methodologies, including determining HLA restriction and recognition in samples from volunteers convalescent from previous infections or immunized with approved or experimental vaccines, and immunophenotyping of responding T cells. The capacity of these regions to induce crossreactive T cell responses can be tested experimentally with homologous peptides derived from the various viral species of interest. Importantly, they could be considered as a component of pan-viral family vaccines. Conversely, immunogenic regions that are highly specific to a given virus could be of interest for diagnostic applications.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-15DOI: 10.2174/0113892010323719241205045837
Saloni Agarwal, Mohd Mazhar, Hiranmoy Saha, Simra Khan, Mohammad Ibrahim, Charu Chhabra
Cosmeceutical products such as skin-lightening agents have been used globally to enhance skin tone and obtain a magnificent outward appearance. The pigment known as melanin, produced by melanocytes, imparts skin color. The Cosmetic Europe survey testifies that most people believe that cosmetics enhance one's quality of life. The most in-demand in the cosmetics industry are skin-whitening agents. Heavy metals and dangerous substances like lead and mercury are present in these skin-brightening cosmetics, which have a long-term effect on important organs and begin asymptomatic. Despite these negative consequences, there is a sizable market for these products due to the desire for fairer skin tones. Cosmetovigilance studies determine the of heavy metals in these preparations, which need to be monitored regularly. This article discusses the toxicity of heavy metals such as nickel, mercury, arsenic, lead, cobalt, and others found in skin-lightening formulas. The acceptable limit for these toxic agents is recognized by several healthcare organizations worldwide.
{"title":"\"Skin Whitening Creams: Cosmetovigilance.\"","authors":"Saloni Agarwal, Mohd Mazhar, Hiranmoy Saha, Simra Khan, Mohammad Ibrahim, Charu Chhabra","doi":"10.2174/0113892010323719241205045837","DOIUrl":"https://doi.org/10.2174/0113892010323719241205045837","url":null,"abstract":"<p><p>Cosmeceutical products such as skin-lightening agents have been used globally to enhance skin tone and obtain a magnificent outward appearance. The pigment known as melanin, produced by melanocytes, imparts skin color. The Cosmetic Europe survey testifies that most people believe that cosmetics enhance one's quality of life. The most in-demand in the cosmetics industry are skin-whitening agents. Heavy metals and dangerous substances like lead and mercury are present in these skin-brightening cosmetics, which have a long-term effect on important organs and begin asymptomatic. Despite these negative consequences, there is a sizable market for these products due to the desire for fairer skin tones. Cosmetovigilance studies determine the of heavy metals in these preparations, which need to be monitored regularly. This article discusses the toxicity of heavy metals such as nickel, mercury, arsenic, lead, cobalt, and others found in skin-lightening formulas. The acceptable limit for these toxic agents is recognized by several healthcare organizations worldwide.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-15DOI: 10.2174/0113892010335576241202061139
Jiao Wang, Tianwei Meng, Na Si, Haihong Li, Yan Yan, Xinghua Li
Background: Dilated Cardiomyopathy (DCM) is a debilitating cardiovascular disorder that challenges current therapeutic strategies. The exploration of novel drug repositioning opportunities through gene expression analysis offers a promising avenue for discovering effective treatments.
Objective: This study aims to identify potential drug repositioning opportunities and lead compounds for DCM treatment by optimizing gene expression characteristics using published data.
Methods: Our approach involved analyzing DCM expression profiles from the Gene Expression Omnibus database and identifying differentially expressed genes with GEO2R. A protein interaction network was constructed using the STRING database and visualized with Cytoscape. Enrichment analyses were conducted on these genes through the Omicshare platform, followed by the identification of candidate compounds via the Connectivity Map (CMAP) and validation through molecular docking. The Coremine Medical database was utilized to predict potential herbal medicines.
Results: We identified 29 differentially expressed genes, highlighting MYH6, NPPA, and NPPB as central to DCM pathology. Enrichment analyses indicated significant impacts on biological processes, such as organ morphogenesis and inflammatory responses. The AGE-RAGE signaling pathway was notably affected. From over 6,100 compounds analyzed, tenoxicam emerged as a promising candidate, with Radix Salviae Miltiorrhizae (Danshen) being suggested as a potential herbal treatment.
Conclusion: This study underscores the utility of bioinformatics in uncovering new therapeutic candidates for DCM, offering a foundational step towards novel drug development.
{"title":"Identifying Novel Therapeutic Opportunities for Dilated Cardiomyopathy: A Bioinformatics Approach to Drug Repositioning and Herbal Medicine Prediction.","authors":"Jiao Wang, Tianwei Meng, Na Si, Haihong Li, Yan Yan, Xinghua Li","doi":"10.2174/0113892010335576241202061139","DOIUrl":"https://doi.org/10.2174/0113892010335576241202061139","url":null,"abstract":"<p><strong>Background: </strong>Dilated Cardiomyopathy (DCM) is a debilitating cardiovascular disorder that challenges current therapeutic strategies. The exploration of novel drug repositioning opportunities through gene expression analysis offers a promising avenue for discovering effective treatments.</p><p><strong>Objective: </strong>This study aims to identify potential drug repositioning opportunities and lead compounds for DCM treatment by optimizing gene expression characteristics using published data.</p><p><strong>Methods: </strong>Our approach involved analyzing DCM expression profiles from the Gene Expression Omnibus database and identifying differentially expressed genes with GEO2R. A protein interaction network was constructed using the STRING database and visualized with Cytoscape. Enrichment analyses were conducted on these genes through the Omicshare platform, followed by the identification of candidate compounds via the Connectivity Map (CMAP) and validation through molecular docking. The Coremine Medical database was utilized to predict potential herbal medicines.</p><p><strong>Results: </strong>We identified 29 differentially expressed genes, highlighting MYH6, NPPA, and NPPB as central to DCM pathology. Enrichment analyses indicated significant impacts on biological processes, such as organ morphogenesis and inflammatory responses. The AGE-RAGE signaling pathway was notably affected. From over 6,100 compounds analyzed, tenoxicam emerged as a promising candidate, with Radix Salviae Miltiorrhizae (Danshen) being suggested as a potential herbal treatment.</p><p><strong>Conclusion: </strong>This study underscores the utility of bioinformatics in uncovering new therapeutic candidates for DCM, offering a foundational step towards novel drug development.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-13DOI: 10.2174/0113892010332329241119104430
Yan Yichao, Li Yongbai, Liang Hailiang, Chen Dongbo, Li Bo, Abduh Murshed
Objectives: This study aimed to comprehensively investigate the molecular landscape of gastric cancer (GC) by integrating various bioinformatics tools and experimental validations.
Methodology: GSE79973 dataset, limma package, STRING, UALCAN, GEPIA, OncoDB, cBioPortal, DAVID, TISIDB, Gene Set Cancer Analysis (GSCA), tissue samples, RT-qPCR, and cell proliferation assay were employed in this study.
Results: Analysis of the GSE79973 dataset identified 300 differentially expressed genes (DEGs), from which COL1A1, COL1A2, CHN1, and FN1 emerged as pivotal hub genes using protein-protein interaction network analysis. Subsequent validation across The Cancer Genome Atlas (TCGA) datasets confirmed their up-regulation in GC tissues compared to normal controls. Promoter methylation analysis revealed decreased methylation levels of these hubs in GC tissues, suggesting their potential role in tumorigenesis. Mutational analysis using cBioPortal showcased frequent mutations in these genes, particularly FN1, further highlighting their significance in GC pathogenesis. Survival analysis indicated their correlation with reduced overall survival rates among GC patients, supported by the development of a robust prognostic model. Prediction of hub-associated miRNAs and gene enrichment analysis provided insights into their regulatory mechanisms and downstream pathways, implicating their involvement in extracellular matrix remodeling and cell migration. Drug sensitivity analysis revealed correlations between hub gene expression and drug response, while RT-qPCR validation confirmed their upregulation in clinical GC samples. Finally, functional assays demonstrated the impact of FN1 knockdown on cellular proliferation, colony formation, and wound healing capacities.
Conclusion: Overall, this study elucidates the crucial role of COL1A1, COL1A2, CHN1, and FN1 in GC pathogenesis and underscores their potential as diagnostic markers and therapeutic targets.
目的:结合多种生物信息学工具和实验验证,全面研究胃癌(GC)的分子格局。方法:本研究采用GSE79973数据集、limma软件包、STRING、UALCAN、GEPIA、OncoDB、cBioPortal、DAVID、TISIDB、Gene Set Cancer Analysis (GSCA)、组织样本、RT-qPCR和细胞增殖试验。结果:通过对GSE79973数据集的分析,鉴定出300个差异表达基因(DEGs),其中COL1A1、COL1A2、CHN1和FN1是关键的枢纽基因。随后通过癌症基因组图谱(TCGA)数据集的验证证实,与正常对照相比,它们在GC组织中的上调。启动子甲基化分析显示,GC组织中这些中心的甲基化水平降低,表明它们在肿瘤发生中的潜在作用。利用cbiopportal进行的突变分析显示,这些基因(尤其是FN1)经常发生突变,进一步强调了它们在GC发病机制中的重要性。生存分析表明它们与GC患者总生存率降低相关,这得到了强大预后模型发展的支持。中心相关mirna的预测和基因富集分析提供了对其调控机制和下游途径的深入了解,暗示它们参与细胞外基质重塑和细胞迁移。药物敏感性分析显示hub基因表达与药物反应之间存在相关性,RT-qPCR验证证实其在临床GC样品中表达上调。最后,功能分析证明了FN1敲除对细胞增殖、菌落形成和伤口愈合能力的影响。结论:总的来说,本研究阐明了COL1A1、COL1A2、CHN1和FN1在胃癌发病机制中的关键作用,并强调了它们作为诊断标志物和治疗靶点的潜力。
{"title":"COL1A1, COL1A2, CHN1, and FN1 Promote Tumorogenesis and Act as Markers of Diagnosis and Survival in Gastric Cancer Patients.","authors":"Yan Yichao, Li Yongbai, Liang Hailiang, Chen Dongbo, Li Bo, Abduh Murshed","doi":"10.2174/0113892010332329241119104430","DOIUrl":"https://doi.org/10.2174/0113892010332329241119104430","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to comprehensively investigate the molecular landscape of gastric cancer (GC) by integrating various bioinformatics tools and experimental validations.</p><p><strong>Methodology: </strong>GSE79973 dataset, limma package, STRING, UALCAN, GEPIA, OncoDB, cBioPortal, DAVID, TISIDB, Gene Set Cancer Analysis (GSCA), tissue samples, RT-qPCR, and cell proliferation assay were employed in this study.</p><p><strong>Results: </strong>Analysis of the GSE79973 dataset identified 300 differentially expressed genes (DEGs), from which COL1A1, COL1A2, CHN1, and FN1 emerged as pivotal hub genes using protein-protein interaction network analysis. Subsequent validation across The Cancer Genome Atlas (TCGA) datasets confirmed their up-regulation in GC tissues compared to normal controls. Promoter methylation analysis revealed decreased methylation levels of these hubs in GC tissues, suggesting their potential role in tumorigenesis. Mutational analysis using cBioPortal showcased frequent mutations in these genes, particularly FN1, further highlighting their significance in GC pathogenesis. Survival analysis indicated their correlation with reduced overall survival rates among GC patients, supported by the development of a robust prognostic model. Prediction of hub-associated miRNAs and gene enrichment analysis provided insights into their regulatory mechanisms and downstream pathways, implicating their involvement in extracellular matrix remodeling and cell migration. Drug sensitivity analysis revealed correlations between hub gene expression and drug response, while RT-qPCR validation confirmed their upregulation in clinical GC samples. Finally, functional assays demonstrated the impact of FN1 knockdown on cellular proliferation, colony formation, and wound healing capacities.</p><p><strong>Conclusion: </strong>Overall, this study elucidates the crucial role of COL1A1, COL1A2, CHN1, and FN1 in GC pathogenesis and underscores their potential as diagnostic markers and therapeutic targets.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's disease (AD) remains a major challenge in developing effective treatments due to its complex pathophysiology, including the accumulation of amyloid-beta plaques and tau tangles. Small interfering RNA (siRNA) technology offers promise for targeted gene silencing, but effective delivery to the central nervous system remains a significant obstacle. Viral vectors have emerged as potent delivery vehicles for transporting siRNA to neural tissues. This review explores the utilization of viral vectors for siRNA delivery in AD, focusing on delivery strategies and challenges. We discuss the design and optimization of viral vectors, targeting strategies, and safety considerations. Additionally, we examine recent advancements and prospects for enhancing viral vector-mediated siRNA delivery in AD.
{"title":"Impact and Significance of Viral Vectors for siRNA Delivery in the Treatment of Alzheimer's Disease.","authors":"Chintan Aundhia, Ghanshyam Parmar, Chitrali Talele, Rahul Trivedi, Mamta Kumari, Jay Chudasama","doi":"10.2174/0113892010334094241112190337","DOIUrl":"https://doi.org/10.2174/0113892010334094241112190337","url":null,"abstract":"<p><p>Alzheimer's disease (AD) remains a major challenge in developing effective treatments due to its complex pathophysiology, including the accumulation of amyloid-beta plaques and tau tangles. Small interfering RNA (siRNA) technology offers promise for targeted gene silencing, but effective delivery to the central nervous system remains a significant obstacle. Viral vectors have emerged as potent delivery vehicles for transporting siRNA to neural tissues. This review explores the utilization of viral vectors for siRNA delivery in AD, focusing on delivery strategies and challenges. We discuss the design and optimization of viral vectors, targeting strategies, and safety considerations. Additionally, we examine recent advancements and prospects for enhancing viral vector-mediated siRNA delivery in AD.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-07DOI: 10.2174/0113892010337908241129055322
Deepa Mundekkad, William C Cho
Introduction: Iron oxide nanozyme was synthesized from the fruit peel extract of pomegranate, which served as a reducing agent during the green synthesis. The scavenging of reactive oxygen species is often accompanied by immunomodulation following antiproliferative effects due to the crosstalk between the proteins involved in the inter-related signaling pathways.
Method: In the current study, the green synthesized nanozyme was studied for its ability to induce apoptosis in breast cancer cell lines. The free radical scavenging effect of the nanozyme was reflected as an extension of its intrinsic endogenous enzyme-mimicking property.
Result & discussion: The cell cycle analysis revealed that the cell death induced by nanozyme mainly affected the G0/G1 phase. The expression of RelA/p65 and the inflammatory mediators affected by the nanozyme established the role of the Fe3O4 nanozyme in immunomodulation along with its antiproliferative activity.
Conclusion: This is the first report on the antiproliferative and immunomodulatory activities expressed by the biomimetic iron oxide nanozyme.
{"title":"Biomimetic Fe3O4 Nanozymes Promote Apoptosis in Breast Cancer Cell Lines via Free Radical Scavenging and Inhibition of RelA/p65.","authors":"Deepa Mundekkad, William C Cho","doi":"10.2174/0113892010337908241129055322","DOIUrl":"https://doi.org/10.2174/0113892010337908241129055322","url":null,"abstract":"<p><strong>Introduction: </strong>Iron oxide nanozyme was synthesized from the fruit peel extract of pomegranate, which served as a reducing agent during the green synthesis. The scavenging of reactive oxygen species is often accompanied by immunomodulation following antiproliferative effects due to the crosstalk between the proteins involved in the inter-related signaling pathways.</p><p><strong>Method: </strong>In the current study, the green synthesized nanozyme was studied for its ability to induce apoptosis in breast cancer cell lines. The free radical scavenging effect of the nanozyme was reflected as an extension of its intrinsic endogenous enzyme-mimicking property.</p><p><strong>Result & discussion: </strong>The cell cycle analysis revealed that the cell death induced by nanozyme mainly affected the G0/G1 phase. The expression of RelA/p65 and the inflammatory mediators affected by the nanozyme established the role of the Fe3O4 nanozyme in immunomodulation along with its antiproliferative activity.</p><p><strong>Conclusion: </strong>This is the first report on the antiproliferative and immunomodulatory activities expressed by the biomimetic iron oxide nanozyme.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}